Immune-correlate analysis of the RV144 vaccine trial revealed that vaccinees with plasma IgA specific to the C1 region of HIV-1 Env gp120 had a higher risk of infection (i.e., decreased vaccine efficacy) than vaccinees without C1-specific IgA antibodies (3). This evidence concerns the gene CD79A and infection.